Definitions need to be precise and consistent: A reply to Haslam with suggestions for the future

In his reply to our critique of research on self-humanizing, Haslam claims that we used a narrow definition of self-humanizing that ignored the evidence from the correlational research he and his colleagues have done. We disagree. First, we relied upon a definition of self-humanizing based upon comparative judgments that Haslam and colleagues have consistently used. Second, we were well aware of the correlational research he and his colleagues have done. We simply did not think, and do not think, these correlations verified the existence of self-humanizing as defined. In his reply, Haslam offered a new definition of self-humanizing that defines self-humanizing in terms of correlations between comparative judgments and ratings of how much traits reflect human nature. Although we believe this change represents some progress, numerous issues in the study of self-humanizing remain to be resolved. We offer some suggestions for future research on this important topic.     

No Matrix Term-Equivalent to Wroński's 3-element Matrix is Finitely Based

Motivated by a question of W. Rautenberg, we prove that any matrix that is term-equivalent to the well-known nonfinitely based matrix of A. Wroski is itself also nonfinitely based.     

Sergei Hessen, Neo-Kantian Dedicated to Professor Andrzej Walicki

This paper commemorates thepresentation of the honorary doctorate, in May2001 by the University of ód, toProfessor Andrzej Walicki. On this occasion,the Honorary Graduate delivered a lecturedevoted to his first philosophy teacher –Sergej Iosifovich Hessen, a prominent RussianNeo-Kantian philosopher and a liberal inmatters social and political. I try to analyzethe main features of Hessen's philosophicalneo-Kantianism, in particular the inevitabilityof a choice between the absolute and therelative both in epistemology and in ethics inthe context of contemporary philosophy.     

Placebo in the investigation of psychotropic drugs,especially antidepressants

The paper presents major ethical, legal and methodological problems related to the use of placebo in mental disorders, especially in depression. It is pointed out that although authoritative groups of experts and numerous publications in the field of psychopharmacology indicate advisability of the double blind design with placebo in clinical trials of antidepressants, in recent years there have been more and more voices questioning legitimacy of this method. Objections of an ethical nature are raised, and reliability of this approach is put into doubt from the methodological viewpoint. These issues are discussed in more detail in the paper. Available alternative solutions should be implemented in psychotropic drug studies. The author shares these objections and doubts of an ethical nature, and believes that the placebo procedure is not a necessity in clinical trials of antidepressants. An earlier version of this paper was presented at an international conference, “Placebo: Its Action and Place in Health Research Today,” held in Warsaw, Poland on 12–13 April, 2003.     

Clinical trials: active control vs placebo — What is ethical?

The quest for effective medicines is very old. In modern times two important tools have been developed to evaluate efficacy of drugs: superiority and non-inferiority types of clinical trials. The former tests the null hypothesis of μ (the difference between a tested drug and comparator) ≤ 0 against μ > 0; the latter tests the null hypothesis of μ ≤ - Δ against, μ > - Δ, where Δ is the clinical difference from the comparator. In a superiority trial, a new drug is tested against a placebo; in a non-inferiority trial, a new drug is tested against active treatment. In this paper, arguments are presented to show that a superiority trial against a placebo is scientifically sound but ethically unacceptable, whereas a non-inferiority trial against active treatment is ethically sound but scientifically not reliable. Switching from a superiority type of trial with placebo to a non-inferiority trial with an active-control — following the latest revision of Declaration of Helsinki — is in practice switching from the violation of the uncertainty principle to uncertainty of results. Given human and financial resources, it appears an academic question as to which is more unethical: to violate patients’ rights or to produce results without scientific value. All presented considerations lead to the conclusion that the use of a superiority trial of design with an active control instead of placebo will satisfy scientific needs, expectation of patients, and the ancient quest for effective medicines. In the era of Good (Clinical, Laboratory, Manufacture) Practice, the attention of those performing clinical trials is focused on the procedure, not always on its essence. However even the excellent performance of a trial which is not worth doing is fruitless. An earlier version of this paper was presented at an international conference, “Placebo: Its Action and Place in Health Research Today,” held in Warsaw, Poland on 12–13 April, 2003.     

Löb's Theorem in a Set Theoretical Setting

We present a semantic proof of Löb's theorem for theories T containing ZF. Without using the diagonalization lemma, we construct a sentence AUT _T, which says intuitively that the predicate autological with respect to T (i.e. applying to itself in every model of T) is itself autological with respect to T. In effect, the sentence AUT _T states I follow semantically from T. Then we show that this sentence indeed follows from T and therefore is true.     

Differential involvement of the central amygdala in appetitive versus aversive learning

Understanding the function of the distinct amygdaloid nuclei in learning comprises a major challenge. In the two studies described herein, we used c-Fos immunolabeling to compare the engagement of various nuclei of the amygdala in appetitive and aversive instrumental training procedures. In the first experiment, rats that had already acquired a bar-pressing response to a partial food reinforcement were further trained to learn that an acoustic stimulus signaled either continuous food reinforcement (appetitive training) or a footshock (aversive training). The first training session of the presentation of the acoustic stimulus resulted in significant increases of c-Fos immunolabeling throughout the amygdala; however, the pattern of activation of the nuclei of the amygdala differed according to the valence of motivation. The medial part of the central amygdala (CE) responded, surprisingly, to the appetitive conditioning selectively. The second experiment was designed to extend the aversive versus appetitive conditioning to mice, trained either for place preference or place avoidance in an automated learning system (INTELLICAGE). Again, much more intense c-Fos expression was observed in the medial part of the CE after the appetitive training as compared to the aversive training. These data, obtained in two species and by means of novel experimental approaches balancing appetitive versus aversive conditioning, support the hypothesis that the central nucleus of the amygdala is particularly involved in appetitively motivated learning processes.